Treatment with 7+3 yields a CR rate of only 20–40% in TP53 mutant AML, with overall survival ranging from 5 to 9 months compared to 33.6 months in TP53 wild-type AML (Figure 2A) [56,86]. Here, TP53 is linked to acute myeloid leukemia.